1. Home
  2. CAPR vs NGS Comparison

CAPR vs NGS Comparison

Compare CAPR & NGS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • CAPR
  • NGS
  • Stock Information
  • Founded
  • CAPR 2005
  • NGS 1998
  • Country
  • CAPR United States
  • NGS United States
  • Employees
  • CAPR N/A
  • NGS N/A
  • Industry
  • CAPR Biotechnology: Biological Products (No Diagnostic Substances)
  • NGS Oilfield Services/Equipment
  • Sector
  • CAPR Health Care
  • NGS Energy
  • Exchange
  • CAPR Nasdaq
  • NGS Nasdaq
  • Market Cap
  • CAPR 324.6M
  • NGS 305.2M
  • IPO Year
  • CAPR N/A
  • NGS 2002
  • Fundamental
  • Price
  • CAPR $6.28
  • NGS $26.20
  • Analyst Decision
  • CAPR Strong Buy
  • NGS Strong Buy
  • Analyst Count
  • CAPR 8
  • NGS 2
  • Target Price
  • CAPR $24.75
  • NGS $32.50
  • AVG Volume (30 Days)
  • CAPR 1.4M
  • NGS 58.3K
  • Earning Date
  • CAPR 08-11-2025
  • NGS 08-11-2025
  • Dividend Yield
  • CAPR N/A
  • NGS 1.53%
  • EPS Growth
  • CAPR N/A
  • NGS 33.85
  • EPS
  • CAPR N/A
  • NGS 1.42
  • Revenue
  • CAPR $13,392,150.00
  • NGS $164,109,000.00
  • Revenue This Year
  • CAPR N/A
  • NGS $9.75
  • Revenue Next Year
  • CAPR $6,061.53
  • NGS $14.27
  • P/E Ratio
  • CAPR N/A
  • NGS $18.41
  • Revenue Growth
  • CAPR N/A
  • NGS 14.77
  • 52 Week Low
  • CAPR $3.98
  • NGS $16.73
  • 52 Week High
  • CAPR $23.40
  • NGS $29.74
  • Technical
  • Relative Strength Index (RSI)
  • CAPR 36.33
  • NGS 57.40
  • Support Level
  • CAPR $6.17
  • NGS $25.05
  • Resistance Level
  • CAPR $7.30
  • NGS $26.54
  • Average True Range (ATR)
  • CAPR 0.43
  • NGS 1.08
  • MACD
  • CAPR -0.11
  • NGS 0.13
  • Stochastic Oscillator
  • CAPR 4.53
  • NGS 81.67

About CAPR Capricor Therapeutics Inc.

Capricor Therapeutics Inc is a clinical-stage biotechnology company focused on the development of transformative cell and exosome-based therapeutics for treating Duchenne muscular dystrophy (DMD), a rare form of muscular dystrophy which results in muscle degeneration and premature death, and other diseases with high unmet medical needs. The company's product pipeline includes CAP-1002, deramiocel an allogeneic cardiac-derived cell therapy. Deramiocel is currently advancing through Phase 3 clinical development for the treatment of Duchenne muscular dystrophy. Through its proprietary StealthXTM platform, the group uses its exosome technology to conduct preclinical research focused on vaccinology, delivering oligonucleotides, proteins, and small molecules to treat.

About NGS Natural Gas Services Group Inc.

Natural Gas Services Group Inc provides natural gas compression equipment and services to the energy industry. The company manufactures, fabricates, rents, sells, and maintains natural gas compressors and flare systems for oil and natural gas production and plant facilities. Its operating units include Rental, Sales, and Aftermarket services. The company generates the majority of its revenue by renting out low- to medium-horsepower compression equipment to natural gas production companies in unconventional oil and gas regions of the United States.

Share on Social Networks: